更换腔内灌注化疗药物对短期复发T_(a)、T_(1)期膀胱癌预后的影响  

Effect of replacing intra-vesical chemotherapy agents on the prognosis of short-term recurring T_(a)and T_(1)stage bladder cancer

作　　者：王意涵 许小林[1] 刘峰[1] 金纪忠[1] 朱鑫 蒋峻宇 王忠[1] WANG Yihan;XU Xiaolin;LIU Feng;JIN Jizhong;ZHU Xin;JIANG Junyu;WANG Zhong(Department of Urology,the South Branch of Shanghai Sixth People's Hospital,Shanghai Jiaotong University,Shanghai,201499,China)

机构地区：[1]上海交通大学附属第六人民医院南院泌尿外科,上海201499

出　　处：《临床泌尿外科杂志》2023年第8期600-604,共5页Journal of Clinical Urology

摘　　要：目的探讨更换腔内灌注化疗药物对短期复发T_(a)、T_(1)期膀胱癌预后的影响。方法回顾性分析2008年1月—2018年12月上海交通大学附属第六人民医院南院收治的316例经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor,TURBT)后1年内复发的T_(a)、T_(1)期膀胱癌患者的临床资料。其中162例患者再次行TURBT后更换腔内灌注化疗药物(试验组)。其他154例患者TURBT术后仍继续应用原来的腔内灌注化疗药物(对照组)。所有患者TURBT术后均即刻灌注腔内化疗药物表柔比星(epirubicin,EPI)、吡柔比星(pirarubicin,THP)或羟基喜树碱(hydroxycamptothecin,HCPT),并随后按疗程进行持续灌注。观察2组患者肿瘤复发及进展情况。结果2组患者(试验组vs对照组)1、3、5年无复发生存率(recurrence-free survival,RFS)分别为95.06%vs 83.12%(χ^(2)=11.73,P<0.01)、72.84%vs 54.55%(χ^(2)=11.46,P<0.01)、53.08%vs 51.30%(χ^(2)=0.10,P=0.82);无进展生存率(progression-free survival,PFS)分别为98.77%vs 92.21%(χ^(2)=8.02,P=0.01)、91.98%vs 85.71%(χ^(2)=3.14,P=0.11)、87.04%vs 83.77%(χ^(2)=0.68,P=0.43)。试验组患者的1、3年RFS及1年PFS明显高于对照组,而2组间5年RFS及3、5年PFS比较差异均无统计学意义。结论TURBT术后更换腔内灌注化疗药物可以显著降低短期复发NMIBC患者的早期复发率,但对于远期预后差异无统计学意义。Objective To evaluate the effect of replacing intra-vesical chemotherapy agents on the prognosis of short-term recurring T_(a)and T_(1)stage bladder cancer.Methods We retrospectively reviewed a consecutive series of 316 patients who had been previously diagnosed with T_(1)or T_(a)urothelial bladder carcinoma and suffered short-term recurrence after initial transurethral resection of the bladder tumor(TURBT)and intra-vesical instillation between January 2008 and December 2018.After a second time TURBT,we immediately changed the intra-vesical instillation agents for 162 patients(study group),whereas the other 154 patients continued to use their initial drugs(control group).All patients received an immediate instillation of epirubicin(EPI),pirarubicin(THP)or hydroxycamptothecin(HCPT)after TURBT and followed by regular maintenance instillations.We compared the recurrence and progression rates between study and control groups.Results The 1-,3-,and 5-year recurrence-free survival(RFS)of the two groups(study group vs control group)were 95.06%vs 83.12%(χ^(2)=11.73,P<0.01),72.84%vs 54.55%(χ^(2)=11.46,P<0.01),53.08%vs 51.30%(χ^(2)=0.10,P=0.82),and progression-free survival(PFS)were 98.77%vs 92.21%(χ^(2)=8.02,P=0.01),91.98%vs 85.71%(χ^(2)=3.14,P=0.11),87.04%vs 83.77%(χ^(2)=0.68,P=0.43),separately.The 1-and 3-year RFS and 1-year PFS of study group were higher than those of control group.However,there were no significant differences in the 5-year RFS or 3-,5-year PFS between the two groups.Conclusion Replacement of intra-vesical chemotherapy agents for short-term recurring T_(a)and T_(1)stage bladder cancer can significantly reduce its early recurrence and progression rates,but have no significant statistical difference on long-term prognosis in this trial.

关 键 词：灌注化疗 膀胱肿瘤 耐药 肿瘤复发 肿瘤进展 

分 类 号：R737.14[医药卫生—肿瘤]